Efectos adversos de los inhibidores de la bomba de protonesrevisión de evidencias y posicionamiento de la Sociedad Española de Patología Digestiva

  1. Cristóbal de la Coba 1
  2. Federico Argüelles Arias 2
  3. Carlos Martín de Argila de Prados 3
  4. Francisco Javier Júdez Gutiérrez 4
  5. Antonio Linares Rodríguez 5
  6. Aida Ortega Alonso 6
  7. Enrique Rodríguez de Santiago 7
  8. Manuel Rodríguez Téllez 2
  9. María Isabel Vera Mendoza 8
  10. Lara Aguilera Castro 7
  11. A. Álvarez Sánchez 9
  12. Raúl J. Andrade Bellido 6
  13. Fidencio Bao 10
  14. M. Castro Fernández 11
  15. Froilán Giganto 12
  1. 1 Hospital de Cabueñes. Gijón, Asturias
  2. 2 Hospital Universitario Virgen Macarena. Sevilla
  3. 3 Hospital Ramón y Cajal
    info

    Hospital Ramón y Cajal

    Madrid, España

    ROR https://ror.org/050eq1942

  4. 4 Departamento Gestión del Conocimiento. SEPD
  5. 5 Sanatorio Nuestra Señora de Covadonga. Gijón, Asturias
  6. 6 Hospital Universitario Virgen de la Victoria.Málaga
  7. 7 Hospital Universitario Ramón y Cajal. Madrid
  8. 8 Hospital Universitario Puerta de Hierro
    info

    Hospital Universitario Puerta de Hierro

    Madrid, España

    ROR https://ror.org/01e57nb43

  9. 9 Hospital Clínico San Carlos de Madrid
    info

    Hospital Clínico San Carlos de Madrid

    Madrid, España

    ROR https://ror.org/04d0ybj29

  10. 10 Hospital de Hospital San Eloy. Barakaldo, Vizcaya
  11. 11 Hospital Universitario de Valme. Sevilla
  12. 12 Hospital Central de Asturias. Oviedo
Mostra les afiliacions +
Revista:
Revista Española de Enfermedades Digestivas

ISSN: 2340-416,  1130-0108

Any de publicació: 2016

Volum: 108

Número: 4

Pàgines: 207-224

Tipus: Article

DOI: 10.17235/REED.2016.4232/2016 DIALNET GOOGLE SCHOLAR

Altres publicacions en: Revista Española de Enfermedades Digestivas

Objectius de Desenvolupament Sostenible

Resum

Introduction: In the last few years a significant number of papers have related the use of proton-pump inhibitors (PPIs) to potential serious adverse effects that have resulted in social unrest. Objective: The goal of this paper was to provide a literature review for the development of an institutional position statement by Sociedad Española de Patología Digestiva (SEPD) regarding the safety of long-term PPI use. Material and methods: A comprehensive review of the literature was performed to draw conclusions based on a critical assessment of the following: a) current PPI indications; b) vitamin B12 deficiency and neurological disorders; c) magnesium deficiency; d) bone fractures; e) enteric infection and pneumonia; f) interactions with thienopyridine derivatives; e) complications in cirrhotic patients. Results: Current PPI indications have remained unchanged for years now, and are well established. A general screening of vitamin B12 levels is not recommended for all patients on a PPI; however, it does seem necessary that magnesium levels be measured at therapy onset, and then monitored in subjects on other drugs that may induce hypomagnesemia. A higher risk for bone fractures is present, even though causality cannot be concluded for this association. The association between PPIs and infection with Clostridium difficile is mild to moderate, and the risk for pneumonia is low. In patients with cardiovascular risk receiving thienopyridines derivatives it is prudent to adequately consider gastrointestinal and cardiovascular risks, given the absence of definitive evidence regardin potential drug-drug interactions; if gastrointestinal risk is found to be moderate or high, effective prevention should be in place with a PPI. PPIs should be cautiously indicated in patients with decompensated cirrhosis. Conclusions: PPIs are safe drugs whose benefits outweigh their potential side effects both short-term and long-term, provided their indication, dosage, and duration are appropriate.

Fuente de los datos: Dialnet